Atypical Presentation of Erythroid/Megakaryocytic Leukemic Transformation of a Myeloproliferative Neoplasm Associated with Mutation and Loss of TP53 [0.03%]
与TP53基因突变和缺失相关的骨髓增殖性肿瘤的红系/巨核细胞白血病不典型转化一例
Brian J Chernak,Filiz Sen,Noushin Farnoud et al.
Brian J Chernak et al.
Case Reports
HemaSphere. 2020 Jul 15;4(4):e411. DOI:10.1097/HS9.0000000000000411 2020
Igor Aurer,Natalia Zing,Massimo Federico
Igor Aurer
Melania Tesio
Melania Tesio
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives [0.03%]
JAK抑制剂治疗骨纤维化的局限性及未来展望
Prithviraj Bose,Srdan Verstovsek
Prithviraj Bose
The 2011 approval of ruxolitinib ushered in the Janus kinase (JAK) inhibitor era in the treatment of myelofibrosis (MF), and 2019 saw the US approval of fedratinib. The first therapeutic agents approved by regulatory authorities for MF, the...
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma [0.03%]
EHA认可ESMO关于初诊和复发套细胞淋巴瘤的临床实践指南
Kim Linton,Martin Dreyling
Kim Linton
Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura [0.03%]
对血栓性血小板减少性紫癜患者的健康素养的认识
Leydi C Velasquez Pereira,Bogac Ercig,Kadri Kangro et al.
Leydi C Velasquez Pereira et al.
Following an acute thrombotic thrombocytopenic purpura (TTP) episode, patients are at risk for relapse, and a careful long-term follow-up is needed. Adherence to the follow-up by patients implies a good understanding of the disease. However...
Nuray Kusadasi,Maaike Sikma,Albert Huisman et al.
Nuray Kusadasi et al.
Recent evidence is focusing on the presence of a hypercoagulable state with development of both venous and arterial thromboembolic complications in patients infected with SARS-CoV-2. The ongoing activation of coagulation related to the seve...
Despina Fotiou,Meletios Athanasios Dimopoulos,Efstathios Kastritis
Despina Fotiou
AL amyloidosis is characterized by a low-level expansion of an indolent, small plasma cell clone that produces amyloidogenic light chains. Amyloid aggregates or preceding intermediaries cause direct cell damage through their proteotoxicity,...
Erik Hameister,Sebastian M Stolz,Yvonne Fuhrer et al.
Erik Hameister et al.
MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease [0.03%]
MEMSID：关于硝吡啶治疗地中海贫血的二期试点研究结果
Inga Hegemann,Clelia Sasselli,Fabio Valeri et al.
Inga Hegemann et al.